The FDA introduced the Commissioner’s National Priority Voucher (CNPV) pilot program, offering accelerated one- to two-month reviews for projects aligned with U.S. health priorities such as onshoring manufacturing, increasing affordability, rare diseases, and chronic disease crisis management. The program expands upon previously announced priorities and clarifies eligibility, aiming to stimulate drug development addressing critical health needs and improving supply chain resilience. FDA continues to encourage applications that demonstrate robust U.S.-based clinical trial enrollment and affordability enhancements.